Xpert® Xpress CoV-2/Flu/RSV plus* - Diagnostic PCR test that detects and differentiates SARS-CoV-2, Flu A, Flu B, and RSV

More coverage. More accuracy. More peace of mind.

In the Xpert Xpress CoV-2/Flu/RSV plus test, the addition of a primer/probe set for the detection of a third SARS-CoV-2 target, RdRP, will add further redundancy and enhance gene coverage to proactively address increasing diversity due to mutations in the N2 and/or E gene targets.

Molecular methods targeting multiple gene targets within the viral genome allow for more reliable detection of strains undergoing genetic variation.

Xpert Xpress CoV-2/Flu/RSV plus has been designed to give healthcare providers confidence in their results and decisions.

Why choose Xpert Xpress CoV-2/Flu/RSV plus*?

Accurate, reliable results to help triage patients during the respiratory season by accurately differentiating between COVID, Influenza and RSV.

 

orange

 

Xpert Xpress CoV-2/Flu/RSV plus Features 

  • Rapid sample-to-answer multiplex
  • 3 gene targets for more reliable detection of SARS-CoV-2

blue

 

One Cartridge, Four Tests

  • Easy to operate
  • Minimal hands-on time
  • Efficient workflow

bright-blue

GeneXpert® Platform

  • Scalable solution from point of care to core lab
  • Modular – versatile to match varying testing demands
  • Reference lab performance in an on-demand easy-to-use format
  • Generates results in real time
  • Continuous flow process - no batch testing

Respiratory Virus Detection with Cepheid’s Diagnostic PCR system

 

Want to see if Xpert Xpress CoV-2/Flu/RSV plus belongs in your lab?

Download data sheet for more details. If you are looking for Cepheid Influenza test or Cepheid Strep A test, see our full respiratory test menu.

References

* This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Request Information

I would like to be part of the Cepheid Community and I understand and consent to receive information about products and services, invitations to virtual and in-person events such as workshops and webinars and educational content from Cepheid and similar information from Cepheid’s affiliates and representatives.

*required fields
Cepheid respects your privacy, and values the relationship with our customers, partners, and associates. Your personal data may be processed by Cepheid, its affiliates, representatives and other Danaher companies for business and marketing purposes. You can review Cepheid Privacy Policy online for additional information on your rights and how we use and share personal data we collect on our websites and other channels. Your consent to receiving Cepheid news can be withdrawn at any time. Building a relationship of trust is important to us and we will happily help with any questions on your personal data processing addressed to Privacy.officer@cepheid.com